Boundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing new cancer treatments for patients with oncogene amplified tumors. The company addresses the unmet need in these patients by studying extrachromosomal DNA (ecDNA), which is a primary cause of oncogene amplification found in 14 to 17% of cancer patients. ecDNA are large circular units of nuclear DNA detected only in cancer cells, not in healthy cells. Patients with oncogene amplified cancers typically show little improvement from current treatments like molecular targeted therapies or immunotherapies and have lower survival rates. Boundless Bio utilizes its proprietary Spyglass platform to identify targets crucial for ecDNA function in oncogene amplified cancer cells. The company then designs and develops small molecule drugs, called ecDNA-directed therapeutic candidates (ecDTx), to inhibit these targets. The goal of these ecDTx is to prevent cancer cells from using chromosomal instability (CIN) and ecDNA amplification biology to grow, adapt, and develop resistance to existing therapies. Unlike traditional targeted therapies that directly target proteins produced by amplified oncogenes, Boundless Bio's ecDTx are designed to be synthetically lethal in tumor cells that depend on ecDNA amplification biology.